Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.78 |
| ▸ | RXRB | P28702 | 4/20 | 0.78 |
| ▸ | RXRG | P48443 | 3/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759214 | 0.94 | RXRA (0.88) | RXRARXRBRXRGPTGER1HPGD | |
| SCHEMBL6606655 | 0.88 | RXRA (0.69) | RXRARXRBRXRGPTGER1HPGD | |
| SCHEMBL5096132 | 0.85 | PTGER1 (1.00) | RXRARXRBRXRGPTGER1CYP2C9 | |
| SCHEMBL5109238 | 0.84 | PTGER1 (0.66) | RXRARXRBRXRGPTGER1MCL1 | |
| SCHEMBL6604669 | 0.83 | RXRA (0.62) | RXRARXRBRXRGPTGER1HPGD | |
| SCHEMBL6605970 | 0.83 | RXRA (0.66) | RXRARXRBRXRGPTGER1HPGD | |
| SCHEMBL5099974 | 0.81 | PTGER1 (1.00) | RXRARXRBRXRGPTGER1MCL1 | |
| SCHEMBL5620525 | 0.81 | PTGER1 (0.77) | RXRARXRBRXRGPTGER1CYP2C9 | |
| SCHEMBL5099740 | 0.81 | PTGER1 (0.71) | RXRARXRBRXRGPTGER1MCL1 | |
| SCHEMBL5100155 | 0.81 | PTGER1 (1.00) | RXRARXRBRXRGPTGER1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | claimed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| JP-2006504767-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | claimed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | claimed |
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | RXRA 4/4885RXRB 1/4885RXRG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.